BUFFALO, NY, January 03, 2022 (GLOBE NEWSWIRE) – 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, nicotine tobacco reduction and enhancement of health and wellness through modern plant science, today announced that company management will participate in two fireside discussion events on Wednesday, January 5.
- Aaron Gray, head of consumer research at Alliance Global Partners, will host an event at 10:30 a.m. EST.
- Vivien Azer, senior beverage, tobacco and cannabis research analyst at Cowen, will host an event at 2:00 p.m. EST.
James A. Mish, Managing Director, Richard Fitzgerald, CFO and Michael Zercher, COO, will attend from 22nd Century.
Fireside Chat events will be available as live webcasts on the 22nd Century website by selecting “Investors” then “Events” or https://www.xxiicentury.com/investors/events. The events will be available as an archive after the live event.
As part of the fireside talks, 22nd Century management will discuss the recent U.S. Food and Drug Administration (FDA) decision to clear the company’s VLN for sale.® King and VLN® Menthol King has reduced nicotine-containing cigarettes as modified risk tobacco products (MRTPs). In doing so, the Agency found that VLN® – which smokes, tastes and smells of a conventional cigarette but contains 95% less nicotine than highly addictive conventional cigarettes – “helps[s] reduce exposure and consumption of nicotine for smokers who use it.
FDA clears VLN for commercialization® with the following MRTP claims in its decision, announced on December 23, 2021:
- “Helps you smoke less. “
- “95% less nicotine. “
- “Helps reduce your nicotine intake. “
- “… Dramatically reduces your nicotine intake. “
VLN®: The lowest nicotine cigarette in the United States
VLN® is the world’s first cigarette that is not designed to create or maintain nicotine addiction. VLN® smokes, smells and tastes like a conventional cigarette and is made from tobacco grown in the USA that contains 95% less nicotine straight from the plant.
FDA Decision to Allow 22nd Century MRTP Claims and Require Additional “Helps You Smoke Less” Claim on Every VLN® pack and in each VLN® The advertisement where one of the other permitted claims is also used was based on a large body of science consisting of dozens of independent scientific and clinical studies using 22nd century reduced nicotine (RNC) tobacco cigarettes. These studies, which were funded in large part by the FDA, National Institutes of Health (NIH), and other US federal government agencies, along with studies funded by 22nd Century, show that smokers who use RNC cigarettes – even those who did not intend to quit early in school – reduce their exposure to and addiction to nicotine, smoke fewer cigarettes per day, increase their number of smoke-free days, and double their attempts to quit. quitting – all with little or no signs of nicotine withdrawal symptoms or compensatory smoking.
22nd Century is ready to supply the market with RNC tobacco and finished products such as VLN® to enable 22nd Century and other manufacturers to comply with the nicotine capsules offered in the United States, New Zealand and other countries as they take this innovative and highly effective harm reduction approach to tobacco first proposed by the World Health Organization (WHO) in 2015. 22nd century herbal technology and products are superior to expensive extraction technologies and similar denicotinization technologies because these technologies generally use chemicals that remove not only the nicotine but also the flavor and aroma compounds, resulting in a product that has been deemed unacceptable to smokers because it does not provide any satisfaction from smoking. In contrast, 22nd century reduced nicotine tobacco naturally grows with very low levels of nicotine, resulting in products that smoke, taste and smell like conventional cigarettes, but contain 95% less nicotine than cigarettes. highly addictive conventional. This is essential to create an acceptable solution and an “exit ramp” for current smokers looking to change their relationship with nicotine.
22nd Century remains committed to licensing its technology and products to each manufacturer to enable industry-wide compliance with the nicotine capsules offered.
About 22nd Century Group, Inc.
22nd Century Group, Inc. (Nasdaq: XXII) is a leading agricultural biotechnology company focused on reducing the harm of tobacco, reducing nicotine tobacco, and improving health and wellness through plant science. With dozens of patents allowing it to control the biosynthesis of nicotine in the tobacco plant, the company has developed proprietary reduced nicotine (RNC) tobacco plants and cigarettes, which have become the cornerstone of the overall plan. of the FDA to combat widespread death and illness caused by smoking. In tobacco, hemp / cannabis and hop plants, 22nd Century uses modern plant breeding technologies including genetic engineering, gene editing and molecular breeding to provide solutions for the life science industries. and consumer products by creating new proprietary plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits.
Learn more at xxiicentury.com, on Twitter @_xxiicentury and on LinkedIn.
Learn more about VLN® at tryvln.com.
Caution regarding forward-looking statements
Except for historical information, all statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements generally contain words such as “anticipate”, “believe”, “consider”, “continue”, “could”, “estimate”, “expect”, “explore”, “foresee”, “objective” , “” Direction “,” intend “,” likely “,” may “,” plan “,” potential “,” predict “,” preliminary “,” probable “,” project “,” promising “,” search for “,” should, “” will “,” would “and similar expressions. Actual results may differ materially from those expressed or implied by forward-looking statements. Significant factors that could cause actual results to differ materially are set out in the “Risk Factors” section of the Company’s Annual Report on Form 10-K filed on March 11, 2021. All information provided in this press release is to as of the date hereof, and the Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
Investor Relations and Media Contact:
Director, Communications and Investor Relations
22nd Century Group, Inc.